The Opioid Use In Turkish Patients With Episodic And Chronic Migraine

  • Yazar/lar BAŞARIR, İlker
    ERTEM, Devrimsel Harika
    ERYİĞİT BARAN, Gözde
    KOCABIYIK, Nurhan
    İLİK, Faik
  • Yayın Türü Konferans Bildirisi
  • Yayın Tarihi 2018
  • Yayıncı SAGE PUBLICATIONS LTD
  • Tek Biçim Adres http://hdl.handle.net/20.500.12498/4519

Introduction: Despite the inadequate evidence of efficacy and safety of the use of opioids for treatment of migraine, it has been reported that patients with severe migraine headaches are prescribed for opioids for pain relief. Drug interactions, abuse, and tolerance are some disadvantages of opioid therapy in migraine. There are studies evaluating opiophobia, prejudice against the use of opioid analgesics by patients and physicians, and the use of opioids for the management of cancer pain in Turkey. However, the opioid use in Turkish migraineurs has not been well documented. Objectives: The aim of this study was to assess the opioid therapy knowledge and use frequency among patients with episodic and chronic migraine. Methods: In this prospective cohort study, we enrolled consecutive migraine patients in our headache clinic during the study period. The diagnosis of migraine was made according to the International Classification of Headache Disorders 3rd edition beta version. The socio-demographic and clinical characteristics were recorded for all patients. Furthermore, patients were asked about the knowledge and use of opioids for migraine headache pain. Results: One hundred patients were enrolled, of which 69 were episodic migraine and 31 were chronic migraine. The mean age of patients was 41.41±12.14, 82 % were female. The duration of migraine was 12.3±10.37 years in episodic migraine and14.2±9.2 years in chronic migraine. Eighty-eight per cent of patients with chronic migraine were treated with at least one preventive treatment. For acute migraine attack treatment, paracetamol, nonsteroidal anti-inflammatory drugs, triptans, and antiemetics were taken in frequency order. All subjects reported that any kind of opioids was not offered or prescribed by general practitioners and neurologists for their headache pain. Besides this, only 8 (8%) patients declared that they heard the use of opioids for the treatment of migraine but they never consulted their doctors. Conclusion: Our results show that opioids are not preferred as an option for acute or preventive migraine treatment by Turkish migraineurs and their physicians.

  • Koleksiyonlar
Erişime Açık
Görüntülenme
2
22.03.2024 tarihinden bu yana
İndirme
1
22.03.2024 tarihinden bu yana
Son Erişim Tarihi
19 Nisan 2024 14:25
Google Kontrol
Tıklayınız
Tam Metin
Tam Metin İndirmek için tıklayın Ön izleme
Detaylı Görünüm
Eser Adı
(dc.title)
The Opioid Use In Turkish Patients With Episodic And Chronic Migraine
Yayın Türü
(dc.type)
Konferans Bildirisi
Yazar/lar
(dc.contributor.author)
BAŞARIR, İlker
Yazar/lar
(dc.contributor.author)
ERTEM, Devrimsel Harika
Yazar/lar
(dc.contributor.author)
ERYİĞİT BARAN, Gözde
Yazar/lar
(dc.contributor.author)
KOCABIYIK, Nurhan
Yazar/lar
(dc.contributor.author)
İLİK, Faik
Atıf Dizini
(dc.source.database)
Wos
Yayıncı
(dc.publisher)
SAGE PUBLICATIONS LTD
Yayın Tarihi
(dc.date.issued)
2018
Kayıt Giriş Tarihi
(dc.date.accessioned)
2020-08-07T14:18:14Z
Açık Erişim tarihi
(dc.date.available)
2020-08-07T14:18:14Z
Kaynak
(dc.source)
CEPHALALGIA
ISSN
(dc.identifier.issn)
0333-1024
Özet
(dc.description.abstract)
Introduction: Despite the inadequate evidence of efficacy and safety of the use of opioids for treatment of migraine, it has been reported that patients with severe migraine headaches are prescribed for opioids for pain relief. Drug interactions, abuse, and tolerance are some disadvantages of opioid therapy in migraine. There are studies evaluating opiophobia, prejudice against the use of opioid analgesics by patients and physicians, and the use of opioids for the management of cancer pain in Turkey. However, the opioid use in Turkish migraineurs has not been well documented. Objectives: The aim of this study was to assess the opioid therapy knowledge and use frequency among patients with episodic and chronic migraine. Methods: In this prospective cohort study, we enrolled consecutive migraine patients in our headache clinic during the study period. The diagnosis of migraine was made according to the International Classification of Headache Disorders 3rd edition beta version. The socio-demographic and clinical characteristics were recorded for all patients. Furthermore, patients were asked about the knowledge and use of opioids for migraine headache pain. Results: One hundred patients were enrolled, of which 69 were episodic migraine and 31 were chronic migraine. The mean age of patients was 41.41±12.14, 82 % were female. The duration of migraine was 12.3±10.37 years in episodic migraine and14.2±9.2 years in chronic migraine. Eighty-eight per cent of patients with chronic migraine were treated with at least one preventive treatment. For acute migraine attack treatment, paracetamol, nonsteroidal anti-inflammatory drugs, triptans, and antiemetics were taken in frequency order. All subjects reported that any kind of opioids was not offered or prescribed by general practitioners and neurologists for their headache pain. Besides this, only 8 (8%) patients declared that they heard the use of opioids for the treatment of migraine but they never consulted their doctors. Conclusion: Our results show that opioids are not preferred as an option for acute or preventive migraine treatment by Turkish migraineurs and their physicians.
Yayın Dili
(dc.language.iso)
en
Tek Biçim Adres
(dc.identifier.uri)
http://hdl.handle.net/20.500.12498/4519
Analizler
Yayın Görüntülenme
Yayın Görüntülenme
Erişilen ülkeler
Erişilen şehirler
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve cerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms